Enrico Patrucco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Enrico Patrucco has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Chiara Ambrogio
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy
31 shared publications - Alessia Mira
Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino 10126, Italy
23 shared publications - Biagio Ricciuti
Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
22 shared publications - Roberto Chiarle
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
19 shared publications - Claudia Voena
Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
17 shared publications - Taek-Chin Cheong
Harvard Medical School
15 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 1 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 1 describes clinical data from patients who showed an ALK fusion following relapse after adagrasib treatment.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 1 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 1 describes clinical data from patients who showed an ALK fusion following relapse after adagrasib treatment.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 10 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 10 presents a schematic representation of the generation of KRAS doxy-inducible models, their validation, the detrimental effect of the co-expression of KRASG12C together with EML-ALK and the response to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 10 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 10 presents a schematic representation of the generation of KRAS doxy-inducible models, their validation, the detrimental effect of the co-expression of KRASG12C together with EML-ALK and the response to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 11 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 11 shows the response of KRAS doxy-inducible models to pan-RAS inhibitor, pan-KRAS inhibitor, KRASG12C inhibitor and ALK inhibitor. It also presents a schematic representation of the design of the in vivo experiment shown in Figure 4, as well as the quantification of Ki67-positive cells in Figure 4C.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 11 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 11 shows the response of KRAS doxy-inducible models to pan-RAS inhibitor, pan-KRAS inhibitor, KRASG12C inhibitor and ALK inhibitor. It also presents a schematic representation of the design of the in vivo experiment shown in Figure 4, as well as the quantification of Ki67-positive cells in Figure 4C.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 2 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 2 shows the validation of the dual KRASG12C/EML4-ALK CRISPR/Cas9 generated models
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 2 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 2 shows the validation of the dual KRASG12C/EML4-ALK CRISPR/Cas9 generated models
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 3 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 3 shows the drug response of dual KRASG12C/EML4-ALK models to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 3 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 3 shows the drug response of dual KRASG12C/EML4-ALK models to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 5 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 5 presents a schematic representation of the selection process undergone by the cells, the response of dual KRASG12C/EML4-ALK long-term (LT) models to KRASG12C inhibitor and ALK inhibitor and the immunohistochemistry (IHC) analysis of Ki67, including its quantification, in tumors treated with KRASG12C inhibitors and ALK inhibitors.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 5 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 5 presents a schematic representation of the selection process undergone by the cells, the response of dual KRASG12C/EML4-ALK long-term (LT) models to KRASG12C inhibitor and ALK inhibitor and the immunohistochemistry (IHC) analysis of Ki67, including its quantification, in tumors treated with KRASG12C inhibitors and ALK inhibitors.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 4 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 4 shows changes in pathway activation in vitro, as well as the response of tumors in vivo to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 4 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 4 shows changes in pathway activation in vitro, as well as the response of tumors in vivo to KRASG12C inhibitor and ALK inhibitor, both alone and in combination.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 6 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 6 shows response and pathway inhibition of dual KRASG12D/EML4-ALK driven models to KRASG12D inhibitor and ALK inhibitor, both alone and in combination.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 6 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 6 shows response and pathway inhibition of dual KRASG12D/EML4-ALK driven models to KRASG12D inhibitor and ALK inhibitor, both alone and in combination.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 7 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 7 shows response and pathway inhibition of dual KRASG12C/CCDC6-RET driven model to KRASG12C inhibitor and RET inhibitor, both alone and in combination.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 7 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 7 shows response and pathway inhibition of dual KRASG12C/CCDC6-RET driven model to KRASG12C inhibitor and RET inhibitor, both alone and in combination.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Suppl. Figure 8 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 8 shows response of dual KRASG12C/EML4-ALK cells to KRASG12C inhibitors, ALK inhibitors, pan-KRAS inhibitor and pan-RAS inhibitor. It also displays the response and pathway inhibition to SHP2 inhibitor, alone or in combination with KRASG12C inhibitors and ALK inhibitors.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl. Figure 8 from EML4−ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway
Suppl. Figure 8 shows response of dual KRASG12C/EML4-ALK cells to KRASG12C inhibitors, ALK inhibitors, pan-KRAS inhibitor and pan-RAS inhibitor. It also displays the response and pathway inhibition to SHP2 inhibitor, alone or in combination with KRASG12C inhibitors and ALK inhibitors.